Anti‐tumor activity of daunorubicin linked to poly‐L‐aspartic acid
- 15 October 1982
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 30 (4) , 465-470
- https://doi.org/10.1002/ijc.2910300413
Abstract
Daunorubicin was bound to poly‐l‐aspartic acid via the methylketone side chain of the drug to avoid reaction of the sugar amino group believed to be essential for optimal drug activity. Attachment of the drug to the poly‐amino acid by an ester linkage was achieved by nucleophylic substitution reaction of 14‐bromo‐daunorubicin. Compared with free daunorubicin, the polymeric derivative was less cytotoxic to HeLa cells in vitro, but more effective against all tumor models tested (P388 leukemia, Gross leukemia, MS‐2 sarcoma). The binding to the poly‐peptide markedly reduced drug toxicity but only slightly decreased drug potency. The daunorubicin‐poly‐L‐aspartic acid conjugate demonstrated antitumor activity comparable to that of doxorubicin in leukemia models, but superior to that of doxorubicin in a solid tumor model (MS‐2 sarcoma).This publication has 23 references indexed in Scilit:
- In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti‐Tumor AntibodiesImmunological Reviews, 1982
- Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugateBiochemical and Biophysical Research Communications, 1981
- TARGETING OF DRUGS: IMPLICATIONS IN MEDICINEThe Lancet, 1981
- Polymeric Antitumor Agents on a Molecular and on a Cellular Level?Angewandte Chemie International Edition in English, 1981
- Preparation and biological properties of a covalent antitumor drug—arm—carrier (DAC conjugate)FEBS Letters, 1980
- Antibodies as specific carriers for chemotherapeutic agentsCancer Chemotherapy and Pharmacology, 1979
- Combination chemotherapy and surgical adjuvant chemotherapy on MS-2 sarcoma and lung metastases in micePublished by Elsevier ,1979
- Biologic characterization and chemotherapeutic response of MS-2 tumor: a non-regressing mouse sarcoma derived from MSV-M-induced sarcomaPublished by Elsevier ,1978
- Higher Antitumor Efficacy of Daunomycin When Linked to Dextran: In Vivo and In Vitro Studies 2JNCI Journal of the National Cancer Institute, 1978
- The use of macromolecules as carriers of antitumor drugsPublished by Elsevier ,1977